Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

The Royal Society For Public Health Announces It Will Be Delivering Training Sessions
The Royal Society for Public Health (RSPH) announces it will be delivering training sessions for the RSPH Level 1 Health Awareness and the RSPH Level 2 Understanding Health Improvement awards.

Youth Baseball-Related Injuries Down 25 Percent, National Study Finds
Spring marks baseball season for more than 19 million children and adolescents who play each year as part of a team or in backyards throughout the United States. The good news for these players is that the number of injuries from the sport is on the decline. A new study by the Center for Injury Research and Policy of The Research Institute at Nationwide Children"s Hospital found that the number of children and adolescents treated for baseball-related injuries in hospital emergency departments decreased 25 percent from 1994 through 2006 - going from an estimated 147,000 injuries in 1994 to approximately 111,000 injuries in 2006. This is the first national study of youth baseball injuries requiring emergency treatment, and is now available online in the June electronic issue of Pediatrics.
News of the day
African-American Women With Advanced Breast Cancer Often Forego Vital Treatment
A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies. Published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that more efforts are needed to ensure that all women with breast cancer receive appropriate care.
Health Insurance

Kineta Acquires Novel Drug Candidates From Airmid For Potential Treatment Of Multiple Sclerosis, Type 1 Diabetes And Other Autoimmune Diseases

Kineta, Inc. of Seattle and Airmid Incorporated of Redwood City, CA jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array of compounds holds extraordinary potential for the treatment of multiple sclerosis, type 1 diabetes mellitus and numerous other autoimmune diseases. "This transaction is a significant milestone for Airmid. It places our peptidic Kv1.3 blockers into the very capable hands of Kineta"s drug development team, sets Airmid on a path to provide substantial return-on-investment for our shareholders, and provides funding to enhance the value of Airmid"s retained assets," said George Miljanich, Ph.D., CEO of Airmid. Under the terms of the deal, Airmid will receive upfront payments, development, regulatory and commercial milestones as well as sales royalties. Airmid founder, K. George Chandy, MD, Ph.D., also applauded the announcement: "Kineta possesses both the scientific capacity and the track record of success necessary to advance these promising therapeutics toward the goal of conquering multiple devastating autoimmune diseases." Following today"s agreement, Kineta One, LLC (a subsidiary of Kineta, Inc.) will aggressively pursue additional preclinical studies on a lead compound. The company intends to file an investigational new drug (IND) application with the FDA and begin clinical trials in 2010. "We are very excited to move forward. Dr. Chandy is an extraordinary scientist who has made an exceptional contribution to the scientific field of autoimmune disease. He will remain an integral advisor to our scientific team," said Kineta President and CEO, Charles Magness, Ph.D. Dr. Chandy, Airmid co-founder Dr. Michael Cahalan and their colleagues at the University of California have spent more than two decades identifying and characterizing ion channels and their role in immune cell function under normal conditions and in autoimmune diseases. Dr. Chandy and his collaborators-Dr. Michael Pennington, Dr. Christine Beeton, Dr. Heike Wulff and Dr. Ray Norton-are credited with discovering an array of novel autoimmune compounds which were later patented. Together they founded Airmid Incorporated. A professor of physiology and biophysics at the University of California, Irvine, Dr. Chandy is an internationally recognized authority on mechanisms of autoimmunity and the role of ion channels in autoimmune disease. The novel class of compounds acquired by Kineta One, LLC today includes potent and highly specific Kv1.3 potassium channel blockers derived from venom of the Caribbean sea anemone. They are designed to suppress activation of effector memory T cells which are important mediators of inflammation and tissue damage in MS, type 1 diabetes and other autoimmune diseases. These compounds have been shown to significantly reverse disease in animal models of multiple sclerosis and rheumatoid arthritis, and also have potential against a number of other autoimmune diseases controlled by effector memory T cells. Animal models also have demonstrated that efficacy is achieved without the generalized immunosuppression that occurs in competing therapies. Kineta, Inc. Airmid Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009